Rivastigmine

Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB) . Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease[1][2].

Product Specifications

CAS Number

[123441-03-2]

Product Name Alternative

ENA 713 (free base) ; SDZ-ENA 713 (free base)

UNSPSC

12352005

Hazard Statement

H300, H411

Target

Cholinesterase (ChE)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Rivastigmine.html

Purity

99.93

Solubility

DMSO : ≥ 50 mg/mL

Smiles

O=C(N(C)CC)OC1=CC=CC([C@H](C)N(C)C)=C1

Molecular Formula

C14H22N2O2

Molecular Weight

250.34

Precautions

H300, H411

References & Citations

[1]Qian-Sheng Yu, et al. Anticholinesterase activity of compounds related to geneserine tautomers. N-Oxides and 1,2-oxazines. J Med Chem. 2002 Aug 15;45 (17) :3684-91.|[2]Han HJ, Lee JJ, Park SA et al. Efficacy and safety of switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch in patients with probable Alzheimer's disease. J Clin Neurol. 2011 Sep;7 (3) :137-42.|[3]Helena Shifrin, et al. Rivastigmine alleviates experimentally induced colitis in mice and rats by acting at central and peripheral sites to modulate immune responses. PLoS One. 2013;8 (2) :e57668.|[4]Raafat A Abdel-Aal, et al. Rivastigmine reverses aluminum-induced behavioral changes in rats. Eur J Pharmacol. 2011 Jun 1;659 (2-3) :169-76.